Alliance Foundation Trials   Report issue

Foundation Phase 2 Phase 3
Founded: Boston MA United States (2014)

Organization Overview

First Clinical Trial
2015
NCT02513394
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alliance Foundation Trials | Alliance Foundation Trials (AFT) | Alliance Foundation Trials, LLC.

Active Ingredients

Drugs in Phase 3 Trials (20)

abiraterone (zytiga) (1 trial)

anastrozole (arimidex) (1 trial)

apalutamide (erleada) (1 trial)

atezolizumab (Tecentriq) (4 trials)

capecitabine (xeloda) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

degarelix acetate (firmagon) (1 trial)

doxorubicin (Doxil) (1 trial)

exemestane (aromasin) (1 trial)

fulvestrant (faslodex) (2 trials)

letrozole (femara) (2 trials)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

paclitaxel (taxol) (4 trials)

palbociclib (ibrance) (4 trials)

pembrolizumab (keytruda) (3 trials)

pertuzumab (perjeta) (1 trial)

prednisone (meticorten) (1 trial)

ribociclib (kisqali) (1 trial)

sacituzumab govitecan (Trodelvy) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (17)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (1 trial)

daratumumab (darzalex) (2 trials)

darolutamide (Nubeqa) (1 trial)

dexamethasone (2 trials)

durvalumab (imfinzi) (1 trial)

enzalutamide (xtandi) (1 trial)

ibrutinib (imbruvica) (2 trials)

ipatasertib (1 trial)

ixazomib (ninlaro) (1 trial)

lenalidomide (revlimid) (2 trials)

nivolumab (opdivo) (2 trials)

pemetrexed (alimta) (1 trial)

pomalidomide (pomalyst) (1 trial)

talazoparib (talzenna) (1 trial)

tiragolumab (1 trial)

topotecan (hycamtin) (1 trial)

Drugs in Other Trials (8)

apixaban (eliquis) (1 trial)

dabigatran (pradaxa) (1 trial)

dalteparin (fragmin) (1 trial)

edoxaban (savaysa) (1 trial)

enoxaparin (lovenox) (1 trial)

fondaparinux sodium (arixtra) (1 trial)

rivaroxaban (xarelto) (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteritis (Phase 1)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Autoimmune Diseases (Phase 1)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colitis (Phase 1)

Colitis, Ulcerative (Phase 1)

Crohn Disease (Phase 1)

Endometrial Neoplasms (Phase 2)

Giant Cell Arteritis (Phase 1)

Lung Neoplasms (Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Multiple Myeloma (Phase 2)

Multiple Sclerosis (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Polymyalgia Rheumatica (Phase 1)

Prostatic Neoplasms (Phase 3)

Psoriasis (Phase 1)

Sclerosis (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 45